Trial Profile
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer - An Open Label, Non-comparative, Randomized, Multicenter Phase II Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Cisplatin; Gemcitabine
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma
- Focus Therapeutic Use
- Acronyms AIO-NIFE; NIFE
- 13 Jun 2023 Planned End Date changed from 1 Jul 2022 to 1 Jan 2025.
- 28 Apr 2021 Planned End Date changed from 1 Jul 2023 to 1 Jul 2022.
- 28 Apr 2021 Status changed from recruiting to active, no longer recruiting.